CANBRIDGE-B (01228): Goruining and Mairebi Included in the First Edition of the Commercial Health Insurance Drug Coverage Cost List

CANBRIDGE-B (01228) announced that Goruining (velaglucerase beta for injection) (Goruining) and Mairebi (maralixibat oral solution) (Mairebi) have been included in the cost list published by the China Association of Actuaries on November 10, 2026. The cost list covers 117 drugs across multiple therapeutic areas including oncology, rare diseases, and chronic diseases, and is intended to solidify the pricing foundation for innovative drug coverage. Both Goruining and Mairebi were selected for the cost list, covering three rare disease indications respectively: Gaucher disease, and Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC). They are expected to benefit the rare disease community by reducing medication burdens through commercial insurance channels. Goruining received marketing approval from China's National Medical Products Administration (NMPA) on May 13, 2025, and is the first domestically developed long-term enzyme replacement therapy indicated for type I and type III Gaucher disease patients aged 12 years and older, including adolescents and adults. As a biologic innovative drug, Goruining can substitute for comparable imported products, and its end-point treatment cost is expected to be significantly lower, which is expected to substantially reduce the economic burden of long-term treatment for patients and fundamentally improve the accessibility and sustainability of medication for Gaucher disease patients worldwide. The company holds exclusive global rights for the development and commercialization of this product, and its first overseas market has been established in the growing North African market. In addition, the company is currently conducting an NMPA-approved registrational clinical trial to expand the eligible population for Goruining to children aged 2 years and under 12 years. Mairebi is a minimally absorbed ileal bile acid transporter inhibitor that blocks the enterohepatic circulation of bile acids, lowers intrahepatic and serum bile acid levels, reduces the resulting liver injury, and relieves cholestatic pruritus (severe itching). As China's first approved product for the treatment of ALGS and PFIC in patients aged 3 months and older, Mairebi launched commercialization in mainland China in 2024 and has to date been included in the Huimin Bao (city-level supplementary medical insurance) programs of 64 cities, covering a population of 299 million in China. On August 14, 2026, Mairebi was approved by Taiwan's National Health Insurance Administration for NHI reimbursement, effective September 1, 2026. The company believes that the inclusion of Goruining and Mairebi in the cost list marks phased progress in the company's efforts to promote multi-tiered coverage and accessibility for rare diseases, and also provides reference pricing information for the design of commercial health insurance products. The company looks forward to leveraging this industry platform to open up commercial insurance coverage pathways and further improve medication accessibility for rare disease patients.